9-Substituted acridine derivatives with long half-life and potent antitumor activity: synthesis and structure-activity relationships
作者:Tsann-Long Su、Ting-Chao Chou、Joong Young Kim、Jai-Tung Huang、Grazyna Ciszewska、Wu-Yun Ren、Grenys M. Otter、Francis M. Sirotnak、Kyoichi A. Watanabe
DOI:10.1021/jm00017a006
日期:1995.8
in culture. Among 9-(3',5'-disubstituted anilino)acridines, 3-(9-acridinylamino)-5-(hydroxymethyl)aniline (AHMA) was found to be a potent topoisomerase II inhibitor and exhibited significant antitumor efficacy both in vitro and in vivo. Chemotherapy of solid-tumor-bearing mice with 10, 10, and 5 mg/kg (QD x 4, ip) AHMA, VP-16, and m-AMSA, respectively, resulted in more tumor volume reduction by AHMA
合成了一系列插入DNA的9-苯胺基cr啶,即9-苯氧基ac啶,9-(苯硫基)ac啶和9-(3',5'-二取代的苯胺基)ac啶,它们可能对DNA拓扑异构酶II具有抑制作用。与氨水扁桃碱(m-AMSA)不同,这些试剂旨在避免氧化代谢途径。因此,预期这些a啶衍生物在血浆中具有长的半衰期。发现9-苯氧基ac啶和9-(苯硫基)ac啶对培养的小鼠白血病L1210和人类白血病HL-60细胞均具有中等细胞毒性。在9-(3',5'-二取代的苯胺基)ac啶中,发现3-(9-ac啶基氨基)-5-(羟甲基)苯胺(AHMA)是有效的拓扑异构酶II抑制剂,在体外和体外均表现出显着的抗肿瘤功效体内。分别以10、10和5 mg / kg(QD x 4,ip)AHMA,VP-16和m-AMSA化疗的实体瘤小鼠,与VP-相比,AHMA减少的肿瘤体积更大16或m-AMSA用于E0771乳腺腺癌和B-16黑色素瘤。对于刘易斯肺癌